Other Events ·
NovaBridge Biosciences presents Phase 1 data for bispecific antibody ragistomig at ESMO Congress
IMABNovaBridge Biosciences
Clinical data from the ongoing Phase 1 clinical trial of ragistomig (ABL503/TJ-L14B), a bispecific antibody targeting PD-L1 and 4-1BB, were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026. The data was presented by ABL Bio Inc., with whom NovaBridge Biosciences is jointly developing the asset, on October 23, 2026, in Madrid, Spain. This disclosure provides preliminary clinical information regarding the company's lead candidate but does not constitute a regulatory approval or commercial milestone. NovaBridge Biosciences operates as a biotechnology company focused on the development of novel immunotherapies.